佛慈制藥(002644.SZ)：截止目前銷售防疫物資2000餘萬元
格隆匯2月12日丨佛慈制藥(002644.SZ)公佈，自2020年1月新型冠狀病毒疫情發生以來，我國多個省市啟動重大突發公共衞生事件一級響應。公司迅速響應，堅決貫徹落實黨中央、國務院、省市黨委政府關於做好疫情防控工作的決策部署，第一時間全面落實疫情防控的各項措施，全面組織防疫物資生產和保供任務，積極履行公司社會責任，為疫情防控攻堅戰貢獻力量。
公司高度重視疫情防控工作，迅速行動，第一時間成立疫情聯防聯控領導小組，設立疫情防控辦公室，及時制定防控工作方案，對各項工作進行嚴密部署，切實排查疫情；及時調整生產經營安排，組織防疫物資生產，全面保障市場供應，全力做好疫情防控各項工作。
1.防疫藥品生產
公司積極安排部署，在春節假期期間公司領導班子及生產員工全面到崗，加班加點組織生產市場急需藥品。2月1日公司全面復工，全力組織生產國家衞生健康委員會發布的《新型冠狀病毒感染的肺炎診療方案(試行第四版)》推薦藥品藿香正氣丸、防風通聖丸、安宮牛黃丸以及板藍根顆粒、銀翹解毒丸等市場急需藥品，全力保障相關藥品市場供應，保障相關藥品不斷貨、不漲價。
2.消毒用品生產
公司於1月31日收到甘肅省衞生健康委員會《關於同意部分企業生產的消毒劑(第一批)用於疫情防控消毒使用的通告》，同意公司在疫情防控期間生產75%乙醇消毒液。獲得主管部門許可後，公司開始加班加點生產75%乙醇消毒液，全力保障市場需求。截止目前，公司已生產75%乙醇消毒液840餘噸，產量佔甘肅省的三分之二以上。
3.防護用品採購
公司積極通過國際市場渠道，自韓國進口KF94口罩40萬隻，有效緩解當地市場口罩急缺形勢。同時，為積極響應政府應對疫情防控所需，緩解疫情防控物資供給壓力，公司擬投資1500萬元建設口罩、防護服生產線，目前已全面開展資質辦理、設備採購、原材料供應、場地淨化等前期準備工作，預計3月上旬設備到貨，力爭3月中下旬投產，日均產能50萬隻。
4.履行社會責任
公司積極履行社會責任，向甘肅省紅十字會、蘭州市紅十字會捐贈價值213萬元新型冠狀病毒感染的肺炎診療方案推薦藥品藿香正氣丸、防風通聖丸、安宮牛黃丸及板藍根顆粒、銀翹解毒丸和75%乙醇消毒液。
公司在嚴格做好疫情防控措施的基礎上，已全面復工，生產經營均按計劃進行，此次疫情暫未對公司生產經營情況造成明顯影響。截止目前，公司銷售防疫物資2000餘萬元，公司口罩、防護服生產線投產後將增加公司新的利潤增長點，對公司未來經營業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
